A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHAMPION-1
- Sponsors Amgen; Onyx Pharmaceuticals
- 04 Jun 2019 Results of post hoc analysis comparing between patients who received Kd56 BIW in the ENDEAVOR trial and patients who received Kd70 QW in the A.R.R.O.W. or CHAMPION-1 trials published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Dec 2018 Results of combined analysis of Carfilzomib trials (CHAMPION-1 , ARROW and ENDEAVOR) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.